查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930094

全球mRNA疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

mRNA Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

mRNA疫苗市場成長驅動因子

全球mRNA疫苗市場正在迅速改變製藥和生物技術產業，其動力來自技術創新、強勁的研發投入以及除新冠肺炎以外的治療應用拓展。根據財富商業洞察（Fortune Business Insights）預測，該市場規模預計將在2025年達到60.1億美元，從2026年的68.5億美元增長到2034年的256.4億美元，預測期內複合年增長率（CAGR）高達17.94%。 2025年，北美市場將以31.47%的市佔率領先，這得益於其先進的醫療基礎設施和積極的研發活動。

市場概覽

信使RNA (mRNA) 疫苗透過誘導細胞產生蛋白質來觸發免疫反應。與傳統疫苗不同，mRNA平台具有開發速度快、靈活性高和可擴展生產等優勢。 COVID-19 mRNA疫苗的成功推出標誌著市場的一個轉捩點，展現了該技術在包括傳染病、自體免疫疾病和腫瘤在內的多種疾病領域的潛力。

人工智慧 (AI) 工具在疫苗開發和臨床試驗中的應用等技術進步正在進一步加速創新。包括Moderna Inc.、輝瑞公司、BioNTech、CureVac SE和葛蘭素史克公司在內的主要公司正在大力投資研發，以拓展其mRNA疫苗產品線。

市場亮點

  • 市場規模（2025年）：60.1億美元
  • 市場規模（2026年）：68.5億美元
  • 市場規模（2034年）：256.4億美元
  • 複合年增長率（2026-2034年）：17.94%

市場快速成長反映了在新冠疫情期間mRNA技術在全球展現其優勢後，人們對該技術的信心日益增強。

市場驅動因素

推動市場成長的主要因素是針對mRNA疫苗的研發活動不斷增加。新冠疫苗的成功促使製藥公司和各國政府探索利用mRNA平台開發流感、呼吸道合胞病毒（RSV）、愛滋病毒（HIV）和其他傳染病疫苗。公共和私營部門的投資持續增加，以支持創新。

例如，Moderna 已宣布計劃在 2024 年至 2028 年間投資約 250 億美元用於研發，以擴大其 mRNA 藥物產品組合。此外，輝瑞的智慧數據查詢 (SDQ) 等人工智慧工具正在提高臨床試驗效率，縮短研發週期，並有助於加快產品上市速度。

市場限制因素與挑戰

儘管成長前景強勁，但由於監管環境嚴格，市場仍面臨挑戰。除緊急情況外，mRNA 疫苗的監管審批流程複雜，包括提交研究性新藥申請 (IND) 和生物製品許可申請 (BLA)，這可能會延遲商業化進程。生產製造的複雜性、冷鏈儲存要求以及大規模生產的限制也阻礙了市場成長，尤其是在資源匱乏的地區。

另一個主要挑戰是由於錯誤訊息和安全擔憂而導致的疫苗猶豫。疫苗接受度的區域差異可能會限制加強劑和新研發的mRNA疫苗的廣泛應用。

市場機會

mRNA疫苗在新冠肺炎以外的應用拓展帶來了巨大的成長機會。目前，針對呼吸道合胞病毒（RSV）、流感、瘧疾和自體免疫疾病的多種候選疫苗正處於臨床開發階段。 mRNA平台的靈活性使其能夠快速適應新出現的病原體，這使其在未來應對大流行病方面具有極高的價值。

此外，製藥公司與國際衛生組織之間日益緊密的合作正在加速創新。例如，BioNTech與流行病防範創新聯盟（CEPI）在被忽視疾病領域的合作，凸顯了mRNA技術應用範圍的不斷擴大。

細分市場考量

依類型劃分，新冠肺炎疫苗作為首批獲批的mRNA疫苗產品，佔了市場主導地位。然而，在不斷擴充的研發管線支持下，非新冠疫苗預計將快速成長。以適應症劃分，新冠病毒感染疫苗佔主導地位，但呼吸道合胞病毒（RSV）疫苗在近期獲得監管部門批准後，展現出強勁的未來潛力。依分銷管道劃分，醫院和零售藥局佔了相當大的佔有率，這得益於政府的疫苗接種計劃。

區域展望

北美市場憑藉強大的研發基礎設施和政府投資，預計將引領市場，2025年達到18.9億美元，2026年達到22.8億美元。歐洲市場在有利的政策和研究機構的支持下位居第二。亞太地區預計將實現顯著增長，這得益於傳染病的日益流行、臨床試驗的擴大以及生物技術投資的增加。世界其他地區（ROW）由於疫苗可及性改善和區域生產擴張，正保持穩定成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要公司新產品發布
  • 主要公司產品線分析
  • mRNA疫苗市場技術進步
  • 主要疾病發生率/盛行率（2025年）
  • 關鍵產業趨勢（併購、合作等）

第五章：全球mRNA疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • COVID-19疫苗
    • 非COVID-19疫苗
  • 市場分析、洞察與預測：依適應症劃分
    • COVID-19感染
    • 呼吸道合胞病毒（RSV）感染
    • 其他
  • 市場分析、洞察與預測：依銷售管道劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 世界其他地區（ROW）

第六章 北美mRNA疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲mRNA疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區mRNA疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：世界其他地區 (ROW) mRNA 疫苗市場分析：洞察與預測（2021-2034）

第十章：競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
  • Moderna Inc.
  • BioNTech
  • CureVac SE
  • GSK plc
  • Sanofi
  • Pfizer Inc.
  • Gennova Biopharmaceuticals Limited
  • Walvax Biotechnology有限公司
  • Arcturus Therapeutics
Product Code: FBI113546

Growth Factors of mRNA vaccines Market

The global mRNA vaccines market is rapidly transforming the pharmaceutical and biotechnology landscape, supported by technological innovation, strong research investments, and expanding therapeutic applications beyond COVID-19. According to Fortune Business Insights, the market was valued at USD 6.01 billion in 2025 and is projected to grow from USD 6.85 billion in 2026 to USD 25.64 billion by 2034, registering a strong CAGR of 17.94% during the forecast period. In 2025, North America dominated the market with a 31.47% share, driven by advanced healthcare infrastructure and strong R&D activity.

Market Overview

mRNA (messenger RNA) vaccines work by instructing cells to produce proteins that trigger an immune response. Unlike traditional vaccines, mRNA platforms enable faster development, higher flexibility, and scalable manufacturing. The successful deployment of COVID-19 mRNA vaccines marked a turning point for the market and validated the technology's potential across multiple disease areas, including infectious diseases, autoimmune disorders, and oncology.

Technological advancements, including the integration of artificial intelligence (AI) tools in vaccine development and clinical trials, have further accelerated innovation. Key players such as Moderna Inc., Pfizer Inc., BioNTech, CureVac SE, and GSK plc are heavily investing in research to expand their mRNA vaccine pipelines.

Market Size Highlights

  • 2025 Market Size: USD 6.01 billion
  • 2026 Market Size: USD 6.85 billion
  • 2034 Market Size: USD 25.64 billion
  • CAGR (2026-2034): 17.94%

The market's rapid growth reflects increasing confidence in mRNA technology following its global validation during the COVID-19 pandemic.

Market Drivers

A major driver of market growth is the increase in R&D activities focused on mRNA-based vaccines. The success of COVID-19 vaccines has encouraged pharmaceutical companies and governments to explore mRNA platforms for influenza, RSV, HIV, and other infectious diseases. Public and private sector investments continue to rise to support innovation.

For instance, Moderna announced plans to invest approximately USD 25 billion in R&D from 2024 to 2028, aimed at expanding its mRNA medicine portfolio. Additionally, AI-powered tools, such as Pfizer's Smart Data Query (SDQ), have improved clinical trial efficiency, reducing development timelines and supporting faster market entry.

Market Restraints and Challenges

Despite strong growth prospects, the market faces challenges from a stringent regulatory landscape. Regulatory approval for mRNA vaccines outside emergency scenarios involves complex processes, including IND and BLA submissions, which may delay commercialization. Manufacturing complexities, cold-chain storage requirements, and large-scale production constraints also hinder growth, especially in low-resource regions.

Another key challenge is vaccine hesitancy, driven by misinformation and safety concerns. Variations in vaccine acceptance across regions can limit uptake, particularly for booster doses and newly developed mRNA vaccines.

Market Opportunities

The expanding applications of mRNA vaccines beyond COVID-19 present significant growth opportunities. Several candidates targeting RSV, influenza, malaria, and autoimmune diseases are currently in the clinical pipeline. The flexibility of mRNA platforms allows rapid adaptation to emerging pathogens, making them highly valuable for future pandemic preparedness.

Additionally, increasing collaborations between pharmaceutical companies and global health organizations are accelerating innovation. Partnerships such as BioNTech's collaboration with CEPI for neglected diseases highlight the growing scope of mRNA technology.

Segmentation Insights

By type, COVID-19 vaccines dominated the market, as they were the first approved mRNA-based products. However, non-COVID-19 vaccines are expected to grow rapidly, supported by pipeline expansion. By indication, COVID-19 infection held the dominant share, while RSV vaccines show strong future potential following recent regulatory approvals. By distribution channel, hospital and retail pharmacies accounted for a significant share, supported by government vaccination programs.

Regional Outlook

North America led the market, with a valuation of USD 1.89 billion in 2025 and USD 2.28 billion in 2026, driven by strong R&D infrastructure and government investments. Europe ranked second, supported by favorable policies and research institutions. Asia Pacific is expected to grow substantially, fueled by rising infectious disease prevalence, increasing clinical trials, and expanding biotechnology investments. The rest of the world is witnessing steady growth due to improved access initiatives and regional manufacturing expansions.

Competitive Landscape

The market is highly concentrated, with Pfizer Inc., Moderna Inc., and BioNTech holding significant shares. These companies continue to strengthen their positions through product innovation, strategic collaborations, and pipeline expansion. Other notable players include CureVac SE, GSK plc, Sanofi, and Arcturus Therapeutics.

Conclusion

In conclusion, the global mRNA vaccines market is poised for robust and sustained growth, expanding from USD 6.01 billion in 2025 to USD 25.64 billion by 2034. Continuous R&D investments, technological advancements, and expanding therapeutic applications are driving market momentum. While regulatory complexities and vaccine hesitancy pose challenges, the proven success and adaptability of mRNA technology position it as a cornerstone of future vaccine development worldwide.

Segmentation By Type

  • COVID-19 Vaccines
  • Non-COVID-19 Vaccines

By Indication

  • COVID-19 Infection
  • Respiratory Syncytial Virus (RSV) Infection
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Indication, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Rest of the World (By Type, Indication, and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the mRNA Vaccines Market
  • 4.4. Incidence/Prevalence of Key Diseases, 2025
  • 4.5. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)

5. Global mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. COVID-19 Vaccines
    • 5.1.2. Non-COVID-19 Vaccines
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. COVID-19 Infection
    • 5.2.2. Respiratory syncytial virus (RSV) Infection
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. COVID-19 Vaccines
    • 6.1.2. Non-COVID-19 Vaccines
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. COVID-19 Infection
    • 6.2.2. Respiratory syncytial virus (RSV) Infection
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. COVID-19 Vaccines
    • 7.1.2. Non-COVID-19 Vaccines
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. COVID-19 Infection
    • 7.2.2. Respiratory syncytial virus (RSV) Infection
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. COVID-19 Vaccines
    • 8.1.2. Non-COVID-19 Vaccines
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. COVID-19 Infection
    • 8.2.2. Respiratory syncytial virus (RSV) Infection
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. COVID-19 Vaccines
    • 9.1.2. Non-COVID-19 Vaccines
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. COVID-19 Infection
    • 9.2.2. Respiratory syncytial virus (RSV) Infection
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. CureVac SE
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. GSK plc
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Sanofi
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Pfizer Inc.
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Gennova Biopharmaceuticals Limited
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Walvax Biotechnology Co., Ltd.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Arcturus Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 3: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global mRNA Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 7: North America mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America mRNA Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 15: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific mRNA Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Rest of the World mRNA Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034a

List of Figures

  • Figure 1: Global mRNA Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global mRNA Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global mRNA Vaccines Market Value Share (%), by Indication, 2025 & 2034
  • Figure 4: Global mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global mRNA Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 8: North America mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 9: North America mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 10: North America mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America mRNA Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America mRNA Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 16: Europe mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 17: Europe mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 18: Europe mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific mRNA Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific mRNA Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World mRNA Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Rest of the World mRNA Vaccines Market Value Share (%), by Type, 2025
  • Figure 32: Rest of the World mRNA Vaccines Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 33: Rest of the World mRNA Vaccines Market Value Share (%), by Indication, 2025
  • Figure 34: Rest of the World mRNA Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Rest of the World mRNA Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Global mRNA Vaccines Market Share (%), By Company, 2025